IN8bio, Inc.: IN8bio focuses on developing allogeneic, autologous and genetically modified gamma-delta T cells therapies for cancer treatments using its DeltEx Platform, based on ex-vivo expanded and activated gamma-delta T cells. First company to advance modified gamma-delta T cells into clinical trials. IN8bio has completed first cohort dosing for its two investigator-initiated Phase 1 clinical trials INB-200 for the treatment of newly diagnosed glioblastoma, which is a difficult to treat brain tumor that progresses rapidly, and INB-100 for the treatment of patients with acute leukemia undergoing hematopoietic stem cell transplantation.